Zacks Investment Research downgraded shares of Opko Health, Inc. (NASDAQ:OPK) from a hold rating to a sell rating in a research note issued to investors on Tuesday morning.

According to Zacks, “OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. “

A number of other equities analysts also recently commented on the stock. BidaskClub downgraded shares of Opko Health from a hold rating to a sell rating in a research note on Saturday, November 11th. Cantor Fitzgerald set a $20.00 target price on shares of Opko Health and gave the stock a buy rating in a research note on Wednesday, October 25th. Ladenburg Thalmann Financial Services restated a buy rating and issued a $16.00 price objective on shares of Opko Health in a research note on Monday, September 25th. J P Morgan Chase & Co downgraded shares of Opko Health from an overweight rating to a neutral rating and decreased their price objective for the company from $12.00 to $7.00 in a research note on Thursday, September 14th. Finally, Jefferies Group LLC restated a hold rating and issued a $6.50 price objective (down previously from $6.80) on shares of Opko Health in a research note on Thursday, August 10th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. The company has an average rating of Hold and a consensus price target of $13.97.

Shares of Opko Health (OPK) traded up $0.07 during mid-day trading on Tuesday, hitting $4.94. 6,014,604 shares of the company were exchanged, compared to its average volume of 4,554,437. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.66 and a quick ratio of 1.48. Opko Health has a 12-month low of $4.50 and a 12-month high of $12.15.

Opko Health (NASDAQ:OPK) last issued its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). The firm had revenue of $263.50 million for the quarter, compared to analyst estimates of $319.43 million. Opko Health had a negative return on equity of 5.17% and a negative net margin of 9.45%. The business’s revenue for the quarter was down 11.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.03) EPS. sell-side analysts anticipate that Opko Health will post -0.27 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Opko Health, Inc. (OPK) Downgraded by Zacks Investment Research to Sell” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.thecerbatgem.com/2017/11/18/opko-health-inc-opk-downgraded-by-zacks-investment-research-to-sell.html.

In other Opko Health news, CEO Phillip Md Et Al Frost bought 25,000 shares of Opko Health stock in a transaction dated Monday, August 21st. The stock was acquired at an average cost of $6.10 per share, with a total value of $152,500.00. Following the completion of the acquisition, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $18,720,601.10. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Opko Health, Inc. bought 655,738 shares of Opko Health stock in a transaction dated Monday, October 30th. The stock was acquired at an average cost of $3.05 per share, with a total value of $2,000,000.90. Following the completion of the acquisition, the insider now directly owns 6,678,752 shares of the company’s stock, valued at approximately $20,370,193.60. The disclosure for this purchase can be found here. Insiders acquired 1,126,038 shares of company stock valued at $4,828,540 in the last 90 days. 40.19% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Credit Suisse AG raised its holdings in Opko Health by 122.0% during the first quarter. Credit Suisse AG now owns 746,958 shares of the biotechnology company’s stock worth $5,976,000 after purchasing an additional 410,445 shares in the last quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD raised its holdings in Opko Health by 14.8% during the second quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD now owns 135,401 shares of the biotechnology company’s stock worth $910,000 after purchasing an additional 17,458 shares in the last quarter. State Board of Administration of Florida Retirement System raised its holdings in Opko Health by 7.5% during the second quarter. State Board of Administration of Florida Retirement System now owns 400,278 shares of the biotechnology company’s stock worth $2,634,000 after purchasing an additional 27,940 shares in the last quarter. Intrinsic Edge Capital Management LLC purchased a new position in Opko Health during the second quarter worth about $658,000. Finally, Balyasny Asset Management LLC raised its holdings in Opko Health by 78.7% during the second quarter. Balyasny Asset Management LLC now owns 40,262 shares of the biotechnology company’s stock worth $265,000 after purchasing an additional 17,728 shares in the last quarter. 22.66% of the stock is owned by hedge funds and other institutional investors.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Get a free copy of the Zacks research report on Opko Health (OPK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Opko Health (NASDAQ:OPK)

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.